Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP) C. Couselo-Rodríguez, A. Batalla, J.M. Carrascosa, P. Chicharro, A. González-Quesada, P. de la Cueva, A.M. Giménez-Arnau, Y. Gilaberte, M. Rodríguez-Serna, T. Montero-Vilchez, R. Ruiz-Villaverde, M. Elosua-González, J.F. Silvestre-Salvador, M. Munera-Campos, J. Sánchez-Pérez, G. Carretero, C. Mauleón-Fernández, L. Curto-Barredo, A. Ballano-Ruiz, R. Botella-Estrada, S. Arias-Santiago, F.J. Navarro-Triviño, G. Roustan-Gullón, I. Betlloch, E. del Alcázar, M.T. Abalde-Pintos, J. Suárez-Perez, I. García-Doval, M.Á. Descalzo, Á. Flórez

Azathioprine for the Treatment of Chronic Spontaneous Urticaria Refractory to Antihistamines, Omalizumab, and Ciclosporin: A Case Series L. Mateu-Arrom, R. Martín, V. Expósito-Serrano, A. Álvarez-Abella, E. Serra-Baldrich, J. Spertino

Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time J.M. Carrascosa, N. Rivera, I. Garcia-Doval, G. Carretero, F. Vanaclocha, E. Daudén, F.J. Gómez-García, P. De-la-Cueva-Dobao, E. Herrera-Ceballos, I. Belinchón, M. Alsina, J.L. Sánchez-Carazo, M. Ferrán, J.L. Lopez-Estebaranz, B. Pérez-Zafrilla, M. Llamas, R. Rivera, C. Ferrándiz